CD20-directed Cytolytic Antibody [EPC]

316949 reported adverse events

Drugs of this class: OBINUTUZUMAB OCRELIZUMAB OCRELIZUMAB AND HYALURONIDASE OFATUMUMAB RITUXIMAB RITUXIMAB AND HYALURONIDASE RITUXIMAB-ABBS RITUXIMAB-ARRX RITUXIMAB-PVVR UBLITUXIMAB

These side effects are most commonly reported by patients taking drugs of the CD20-directed Cytolytic Antibody [EPC] class:

# Side effect Count
0 OFF LABEL USE 46220
1 DRUG INEFFECTIVE 38231
2 FATIGUE 29593
3 PAIN 24308
4 RHEUMATOID ARTHRITIS 20550
5 COVID-19 20005
6 HEADACHE 18273
7 PYREXIA 17520
8 INFUSION RELATED REACTION 16734
9 PNEUMONIA 16561
See all common reactions for CD20-directed Cytolytic Antibody [EPC]

Drugs of the CD20-directed Cytolytic Antibody [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE 5905 0.8233
1 PEMPHIGUS 9588 0.7661
2 SWOLLEN JOINT COUNT INCREASED 2395 0.7503
3 RHEUMATIC FEVER 3322 0.7445
4 RHEUMATOID FACTOR POSITIVE 4269 0.7383
5 DUODENAL ULCER PERFORATION 5087 0.6834
6 FACET JOINT SYNDROME 2136 0.6554
7 HAND DEFORMITY 7884 0.6005
8 HELICOBACTER INFECTION 5257 0.5110
9 SYNOVITIS 8962 0.4965
See all enriched reactions for CD20-directed Cytolytic Antibody [EPC]